Special Issue "Metal Arene Complexes"

A special issue of Inorganics (ISSN 2304-6740). This special issue belongs to the section "Organometallic Chemistry".

Deadline for manuscript submissions: 30 June 2021.

Special Issue Editor

Prof. Dr. Bruno Therrien
E-Mail Website
Guest Editor
Institut de Chimie, Université de Neuchâtel, Avenue de Bellevaux 51, CH-2000 Neuchâtel, Switzerland
Interests: metalla-assemblies; supramolecular chemistry; host-guest chemistry; metal-based drugs; organometallic chemistry; X-ray crystallography
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

For very good reasons, metal arene complexes are among the most studied organometallic complexes. In such complexes, the arene ligand plays crucial roles that are often underestimated. In catalysis, for example, the arene ligand is not considered directly involved in the catalytic process; however, it ensures electronic and structural stability at the metal center, and if properly designed, it can introduce steric hindrance and dictate how the substrate will bind to the metal. In medicinal chemistry, the arene is also important, despite being often seen as an innocent ligand. In biological media, it can modulate the solubility of the complex, and accordingly trigger different responses in cells. In supramolecular chemistry, the presence of the arene limits the number of coordination sites available on the metal, thus, allowing geometric control during the assembly process. These are only a few examples, where the characteristics of metal arene complexes have been nicely exploited. In this Special Issue, we would like to gather all kinds of studies in which the metal arene complex is central. Therefore, all contributions involving metal arene complexes are welcome.

Prof. Dr. Bruno Therrien
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Inorganics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Arene ligand
  • Catalysis
  • Bioinorganic chemistry
  • Supramolecular chemistry
  • Coordination complexes
  • Organometallic chemistry
  • Metal-based drugs
  • Piano-stool complexes

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle
Synthesis and Structural Characterization of Half-Sandwich Arene–Ruthenium(II) Complexes with Bis(imidazol-1-yl)methane, Imidazole and Benzimidazole
Inorganics 2021, 9(5), 34; https://doi.org/10.3390/inorganics9050034 - 04 May 2021
Viewed by 150
Abstract
Mono- and binuclear arene–ruthenium(II) complexes with imidazole-containing ligands were prepared by the reaction of the ligands (L1 = bis(imidazole-1-yl)methane; ImH = 1H-Imidazole; BImH = 1H-Benzimidazole) with [(p-cym)Ru(µ-Cl)2]2 dimers. When bis(imidazole-1-yl)methane reacted with [( [...] Read more.
Mono- and binuclear arene–ruthenium(II) complexes with imidazole-containing ligands were prepared by the reaction of the ligands (L1 = bis(imidazole-1-yl)methane; ImH = 1H-Imidazole; BImH = 1H-Benzimidazole) with [(p-cym)Ru(µ-Cl)2]2 dimers. When bis(imidazole-1-yl)methane reacted with [(p-cym)Ru(µ-Cl)2]2 in methanol, a binuclear complex of the type [Ru2(L1)2(p-cym)2Cl2]Cl2 (2) with cyclic structure was synthesized, whereas by using acetonitrile as a solvent under the same reaction conditions, an unexpected C–N bond cleavage was observed, and a complex of formula [Ru(ImH)2(p-cym)Cl]Cl (1) with coordinated imidazole molecules was obtained. Another type of arene–ruthenium complex [Ru(BImH)(p-cym)Cl2] (3) was obtained by the reaction of benzimidazole and [(p-cym)Ru(µ-Cl)2]2. All compounds were characterized by spectral (FT-IR, NMR 1H, 13C) and single-crystal X-ray diffraction methods; their catalytic activity in transfer hydrogenation and the cytotoxicity against MCF-7 and HepG2 cells were evaluated. Full article
(This article belongs to the Special Issue Metal Arene Complexes)

Review

Jump to: Research

Open AccessReview
Anticancer Half-Sandwich Rhodium(III) Complexes
Inorganics 2021, 9(4), 26; https://doi.org/10.3390/inorganics9040026 - 08 Apr 2021
Viewed by 389
Abstract
Platinum-based anticancer drugs are most likely the most successful group of bioinorganic compounds. Their apparent disadvantages have led to the development of anticancer compounds of other noble metals, resulting in several ruthenium-based drugs which have entered clinical trials on oncological patients. Besides ruthenium, [...] Read more.
Platinum-based anticancer drugs are most likely the most successful group of bioinorganic compounds. Their apparent disadvantages have led to the development of anticancer compounds of other noble metals, resulting in several ruthenium-based drugs which have entered clinical trials on oncological patients. Besides ruthenium, numerous rhodium complexes have been recently reported as highly potent antiproliferative agents against various human cancer cells, making them potential alternatives to Pt- and Ru-based metallodrugs. In this review, half-sandwich Rh(III) complexes are overviewed. Many representatives show higher in vitro potency than and different mechanisms of action (MoA) from the conventional anticancer metallodrugs (cisplatin in most cases) or clinically studied Ru drug candidates. Furthermore, some of the reviewed Rh(III) arenyl complexes are also anticancer in vivo. Pioneer anticancer organorhodium compounds as well as the recent advances in the field are discussed properly, and adequate attention is paid to their anticancer activity, solution behaviour and various processes connected with their MoA. In summary, this work summarizes the types of compounds and the most important biological results obtained in the field of anticancer half-sandwich Rh complexes. Full article
(This article belongs to the Special Issue Metal Arene Complexes)
Show Figures

Figure 1

Back to TopTop